26th week of 2013 patent applcation highlights part 41 |
Patent application number | Title | Published |
20130164177 | BIOWASTE STERILIZER - Biowaste sterilizers are described. In one implementation an exemplary system has waste transport vessels that can be intermittently heated and pressurized, for example, with steam, and are interconnected to provide multiple sterilization pathways for waste as the waste is transported. Selected sterilization pathways may depend on attributes of the waste. Sterilization factors, such as mechanical shredding, application of steam, application of pressure, maintenance of temperature, separation of liquid, etc., are integrated into the waste transport features of the system, which can be made compact to save space while processing relatively large bulk amounts of materials, such as medical wastes. The system maintains safe isolation of bio-hazardous components in the waste from the external environment. A system controller provides parameters management, smart sterilization cycle control, quality assurance, safety management, diagnostics, and reporting over a network. | 2013-06-27 |
20130164178 | Fragrance Dispenser for use with portable electronic device - A cover for holding and protecting a scent insert for use with a portable electronic device or other electronic device such as an IPOD, IPAD, MP3 player, laptop, for example, including a pocket for holding a removable scented insert. The pocket is an integral part of the cover or a removable pocket which is held on to the outside of the cover with an adhesive, for example. The aromatic insert is a scent impregnated porous plastic insert or plastic insert having a permeable layer sealed with nonpermeable peelable layers of plastic or paper film wherein a top layer is removed as desired, thus releasing the desired aroma. The exterior surface of the pocket is porous or includes apertures or slits for transferring the scent outside of the pocket insert holder. | 2013-06-27 |
20130164179 | FLAMELESS STEAM REFORMER - A flameless steam reformer is provided, which includes a main housing, a catalyst housing which is inserted to the main housing and in which a combustion catalyst and a reforming catalyst are provided such that they are partitioned from each other, and a passage housing which is disposed between the main housing and the catalyst housing and includes a passage through which a reforming fuel supplied to the catalyst housing moves. | 2013-06-27 |
20130164180 | Method And Apparatus For Manufacturing Hydrogen-Containing Gas - There is provided a technique and an apparatus for manufacturing a hydrogen-containing gas. An oxygen-containing gas is mixed with a feed gas obtained by mixing steam with a hydrocarbon fuel, this mixture is introduced into a catalytic reaction chamber, and a partial oxidation reaction and a steam reforming reaction are conducted to obtain a hydrogen-containing gas. In this reforming, an antechamber of the catalytic reaction chamber is heated up to a self-ignition temperature in a first catalyst section, where the self-ignition temperature is the temperature at which a mixed gas self-ignites during the advection period required for the mixed gas to move from a mixing chamber to the catalytic reaction chamber, with this temperature being at least a minimum partial-oxidation temperature and lower than a minimum steam reforming temperature. | 2013-06-27 |
20130164181 | REDUCING AGENT AQUEOUS SOLUTION MIXING DEVICE AND EXHAUST GAS POST-TREATMENT DEVICE - A reducing agent aqueous solution mixing device includes an exhaust pipe, an injector, an inner pipe and a tubular guide member. The exhaust pipe includes an elbow part having a curved portion, and a linear part disposed on a downstream side of the elbow part. The injector is disposed outside the curved portion and injects only a reducing agent aqueous solution into the elbow part towards the linear part. The inner pipe is disposed on an exhaust stream downstream side of the injector within the exhaust pipe with an inlet portion opening thereof facing the injector and an outer peripheral surface thereof being spaced apart from the inner wail of the linear art. The inner pipe allows the exhaust as to flow through the inside thereof and the outer periphery thereof. A tubular guide member directs the reducing agent aqueous solution injected from the injector to the inner pipe. | 2013-06-27 |
20130164182 | REDUCING AGENT AQUEOUS SOLUTION MIXING DEVICE AND EXHAUST GAS POST-TREATMENT DEVICE - A reducing agent aqueous solution mixing device includes an exhaust pipe, an injector, a mixing pipe and an inner pipe. The exhaust pipe includes an elbow part having a curved portion, and a linear part disposed on the downstream side of the elbow part. The injector is disposed outside the curved portion and injects the reducing agent aqueous solution towards the linear part. The mixing pipe is disposed inside the elbow part to enclose a surrounding of the reducing agent aqueous solution injected from the injector, and includes a plurality of openings on an outer peripheral surface thereof. The inner pipe is disposed on the downstream side of the mixing pipe and spaced apart from an outlet portion of the mixing pipe and from an inner wall of the linear part, and allows the exhaust gas to flow through the inside thereof and the outer periphery thereof. | 2013-06-27 |
20130164183 | REDUCING AGENT AQUEOUS SOLUTION MIXING DEVICE AND EXHAUST GAS POST-TREATMENT DEVICE - A reducing agent aqueous solution mixing device includes an exhaust pipe, an injector, a mixing pipe, an inner pipe and a flow section. The exhaust pipe includes an elbow part and a linear part. The injector is disposed in the elbow part and injects a reducing agent aqueous solution. The mixing pipe is disposed to enclose a surrounding of the reducing agent aqueous solution injected from the injector, and includes an outlet portion formed spaced apart from an inner wall of the exhaust pipe, and a plurality of openings formed on the outer peripheral surface thereof. The inner pipe is disposed in the linear part and allows the exhaust gas to flow through the inside and the outer periphery thereof. The flow section is formed between the outlet portion of the mixing the inner wall of the exhaust pipe and directs the exhaust gas to the inner pipe. | 2013-06-27 |
20130164184 | AUTOMOTIVE ANIT-CONTAMINATION SYSTEM - An anti-contamination system having a container, a pump, a tube, an exhaust pipe, and a dispenser system. The pump is used to direct a water and calcium oxide solution through the tube to the dispenser system. The high temperature of the exhaust gases is used as a reactor and the exhaust pipe as a controlled atmosphere volume. The heat from the exhaust gas/pipe is used to heat water mixed with calcium oxide to create calcium hydroxide and steam, which is injected by the dispenser system into the exhaust pipe such that the exhaust gas reacts with the steam and the calcium hydroxide. The exhaust pipe is made with stainless steel to avoid corrosion due the chemical reactions that occur inside, and the gases expelled to the atmosphere are clean with only minimal solid residues like calcium sulfate that are troughed away as small pellets, without any pollution contribution. | 2013-06-27 |
20130164185 | ELECTRICALLY HEATED CATALYST - The flow of electricity to the case ( | 2013-06-27 |
20130164186 | SYSTEMS AND METHODS FOR REDUCING OFF-GASSED OZONE - Systems and methods for producing an ozone destructor are disclosed herein. Generally, these systems and methods include an ozone destructor that has a housing defining an air passage duct. In some cases, this air passage duct includes a first chamber and a second chamber that are arranged so that air is able to flow into the first chamber, through the second chamber, and out of the destructor. In some cases, an air drying mechanism is disposed in the first and/or the second chamber. Additionally, in some cases, the ozone destructor further includes multiple mechanisms that reduce ozone to oxygen. In light of these features, the ozone destructor is capable of incrementally drying and reducing air and ozone, respectively, as they pass through the first chamber and the second chamber. | 2013-06-27 |
20130164187 | Production Apparatus of Composite Silver Nanoparticle - A production apparatus of composite silver nanoparticle including: a device for arranging a silver salt microparticle and at least an alcohol solvent selected from alcohols having a carbon number of 1 to 12; a raw material mixer for preparing an alcohol solution by mixing the silver salt microparticle into the alcohol solvent added more excessively than the mol number of the silver salt microparticle to make an excess alcohol solution; a reactor for generating a composite silver nanoparticle by heating the excess alcohol solution at a generation temperature PT generating an aldehyde for a generation time with a heater, in which a silver core is formed by reducing the silver salt microparticle by the alcohol solvent and/or the aldehyde and the composite silver nanoparticle having an organic coating layer originated from the alcohol solvent around the silver core is formed, and a chiller for cooling the alcohol solution | 2013-06-27 |
20130164188 | ELECTRICALLY HEATED CATALYST - Electricity is suppressed from flowing to a case ( | 2013-06-27 |
20130164189 | Syringe Sterilization Cap - A sterilization cap carried on a needle support end of a syringe. The cap includes a main body having first and second ends, the first end being connectable to the needle support end, as well as being connectable onto the needle support end alone of a primary or IV extension line. A sponge secured within a sponge cavity within the second end is saturated with a sterilizing liquid. A removable cover attached to the second sealingly encloses the sponge until the syringe is used. The second end is sized, when the cover is removed, to fit over a clave tip of a clave extension or IV tubing a distance sufficient to compress the sponge to sterilize the clave tip with sterilizing liquid expressed from the sponge. | 2013-06-27 |
20130164190 | Sample Collection System with Integrated Drug Testing Apparatus - A urine sample collection and drug test kit includes a receiving vessel with a specially prepared mechanical holder. A prepared chemical test carrier insert is pushed into the holder to form a drug test system. The drug test kit additionally includes purpose functional cap integrated with the receiving vessel whereby a sure liquid tight seal is easily established by merely applying a pressure to the cap to complete a press fit seal between the cap and receiving vessel at their respective aperture peripheries. The carrier insert is fashioned to accommodate an array of drug test reagent strips, for example nitrocellulose strips having prescribed chemistry integrated thereon. Receiving vessels of these systems are particularly characterized in that they include a viewing window carefully aligned with respect to the mechanical holder whereby the carrier insert may be viewed as it is held indexed and fixed with respect to the exterior surface of the receiving vessel. | 2013-06-27 |
20130164191 | MICROFLUIDIC DEVICES WITH INTEGRATED RESISTIVE HEATER ELECTRODES INCLUDING SYSTEMS AND METHODS FOR CONTROLLING AND MEASURING THE TEMPERATURES OF SUCH HEATER ELECTRODES - The invention relates to methods and devices for control of an integrated thin-film device with a plurality of microfluidic channels. In one embodiment, a microfluidic device is provided that includes a microfluidic chip having a plurality of microfluidic channels and a plurality of multiplexed heater electrodes, wherein the heater electrodes are part of a multiplex circuit including a common lead connecting the heater electrodes to a power supply, each of the heater electrodes being associated with one of the microfluidic channels. The microfluidic device also includes a control system configured to regulate power applied to each heater electrode by varying a duty cycle, the control system being further configured to determine the temperature of each heater electrode by determining the resistance of each heater electrode. | 2013-06-27 |
20130164192 | Microfluidic Capsule - A microfluidic capsule ( | 2013-06-27 |
20130164193 | SEQUENTIAL LATERAL FLOW CAPILLARY DEVICE FOR ANALYTE DETERMINATION - Disclosed is a lateral flow capillary device and uses thereof comprising a unipath capillary flow matrix and a plurality of reservoirs each in fluid communication with the capillary flow matrix. The device includes one or more pressure delivery systems configured to urge capillary flow matrix toward a portion of the housing in which it resides, such that a substantially uniform pressure is applied over a portion of the capillary flow matrix. | 2013-06-27 |
20130164194 | PIPETTE TIPS - Disclosed here are pipette tips useful for acquiring or dispelling liquids, and include one or more design that may increase fluid delivery precision and/or accuracy, and may reduce certain repetitive motions. | 2013-06-27 |
20130164195 | Density Phase Separation Device - A mechanical separator for separating a fluid sample into first and second phases is disclosed. The mechanical separator includes a float having a passageway extending between first and second ends thereof with a pierceable head enclosing the first end of the float, a ballast longitudinally moveable with respect to the float, and a bellows extending between a portion of the float and a portion of the ballast. The bellows is adapted for deformation upon longitudinal movement of the float and the ballast, with the bellows isolated from the pierceable head. The float has a first density and the ballast has a second density greater than the first density. The bellows is structured for sealing engagement with a cylindrical wall of a tube, and the pierceable head is structured for application of a puncture tip therethrough. The separation device is suitable for use with a standard medical collection tube. | 2013-06-27 |
20130164196 | MULTI-WELL ROTARY SYNTHESIZER - An apparatus for synthesizing polymer chains includes a controller, a plurality of precision fit vials circularly arranged in multiple banks on a cartridge, a drain corresponding to each bank of vials, a chamber bowl, a plurality of valves for delivering reagents to selective vials, and a waste tube system for purging material from the vials. A purging operation can be selectively performed on one or more of the banks of vials. The plurality of vials are stored in the cartridge and are divided among individual banks wherein each bank of vials has a corresponding drain. There is at least one waste tube system for expelling the reagent solution from vials within a particular bank of vials when the waste tube system is coupled to the corresponding drain. The cartridge holding the plurality of vials rotates relative to the stationary banks of valves and the waste tube system. | 2013-06-27 |
20130164197 | EXTRACTION OF URANIUM FROM WET-PROCESS PHOSPHORIC ACID - In a preferred embodiment, a process for extracting uranium from wet-process phosphoric acid (WPA), comprises separating uranium from WPA to produce a loaded uranium solution stream and a uranium depleted WPA stream. The loaded uranium solution stream is then contacted by with an ion exchange resin. Uranium species bound to the ion exchange resin are eluted by contacting the resin with a solution comprising anions to produce a loaded uranium eluant stream. The loaded uranium eluant stream is treated to provide a uranium containing product. | 2013-06-27 |
20130164198 | Recovery Method for a Continuous Calcium Extraction and PCC Production - A method of mineralizing calcium from industrial waste comprising extracting calcium ions from a suspension of calcium rich granular particles and aqueous ammonium nitrate to form a calcium-rich first fraction and a heavy second fraction. The heavy second fraction is separated from the first fraction and the calcium-rich first fraction is carbonated with a gas comprising carbon dioxide to form a suspension of precipitated calcium carbonate and aqueous ammonium nitrate. The precipitate is separated from the aqueous ammonium nitrate by centrifugal means and the separated heavy second fraction comprises an enriched weight percent of iron. | 2013-06-27 |
20130164199 | REGENERABLE SOLVENT MIXTURES FOR ACID-GAS SEPARATION - A solvent system comprising an ionic Liquid formed from a relatively acidic component and a nitrogenous base for the removal of acid gases from mixed gas streams is provided. Also provided is a process for removing acid gases from mixed gas streams using the disclosed solvent system. The solvent system may be utilized within a gas processing system. | 2013-06-27 |
20130164200 | REGENERABLE SOLVENT MIXTURES FOR ACID-GAS SEPARATION - A solvent system comprising a diluent and a nitrogenous base for the removal of CO | 2013-06-27 |
20130164201 | COMPOSITION BASED ON CERIUM, ZIRCONIUM AND TUNGSTEN, PREPARATION PROCESS AND USE IN CATALYSIS - A composition based on cerium, zirconium and tungsten is described. The composition has a content expressed as an oxide, of which cerium is from 5% to 30% of the composition, tungsten is from 2% to 17% of the composition, and the remainder of the composition is zirconium. After aging at 750° C. under an air atmosphere including 10% water, it has a two-phase crystallographic structure having a tetragonal zirconia phase and a monoclinic zirconia phase, with no presence of a crystalline phase including tungsten. The composition can be used as a catalyst, especially in an SCR process. | 2013-06-27 |
20130164202 | RECIRCULATED-SUSPENSION PRE-CALCINER SYSTEM - A recirculated-suspension pre-calciner system is disclosed, comprising: a vortex cyclone dust collecting equipment including a plurality of devices, wherein a top device of the vortex cyclone dust collecting equipment is used as a feed system; a vertical combustion kiln; a blower; and a powder purge system, wherein powders in the feed system fall into the vortex cyclone dust collecting equipment and pass through a plurality of the devices to mix and exchange heat with flue gas comprising CO | 2013-06-27 |
20130164203 | CO2 RECOVERY SYSTEM AND CO2 RECOVERY METHOD | 2013-06-27 |
20130164204 | SOLVENT COMPOSITION FOR CARBON DIOXIDE RECOVERY - The present disclosure provides for a solvent composition for recovery of carbon dioxide from gaseous mixture, comprising diethanolamine, piperazine or its derivative, alkali salt, optionally along with cupric carbonate. The disclosure relates to improved solvent formulations that utilizes less energy and increased carbon capture efficiency. The disclosure also addresses the high CO | 2013-06-27 |
20130164205 | HETEROPOLY ACID PROMOTED CATALYST FOR SCR OF NOx WITH AMMONIA - The present invention concerns the selective removal of nitrogen oxides (NOx) from gases. In particular, the invention concerns a process, a highly alkali metal resistant heteropoly acid promoted catalyst and the use of said catalyst for removal of NOx from exhaust or flue gases, said gases comprising alkali or earth alkali metals. Such gases comprise for example flue gases arising from the burning of biomass, combined biomass and fossil fuel, and from waste incineration units. The process comprises the selective catalytic reduction (SCR) of NOx, such as nitrogen dioxide (NO | 2013-06-27 |
20130164206 | CALCIUM CARBONATE HAVING A SURFACE CHARGE, THE PREPARING PROCESS THEREOF AND FILLER FOR PRODUCING A PAPER USING THE SAME - The present invention relates to a calcium carbonate having a surface charge, the preparing process thereof and filler for producing a paper using the same. The present invention provides the process of preparing a calcium carbonate having a surface charge, characterized in that it comprises the following steps of: preparing a solution mixture of one or more monomer selected from the group consisting of calcium hydroxide, acrylic acid, acrylamide, or [2-(acryloyloxy)ethyl]-trimethylammonium chloride; removing dissolved gases such as oxygen and carbon dioxide in the said solution by injecting nitrogen (N | 2013-06-27 |
20130164207 | COMPOSITE RAW MATERIAL, CARBON FIBER MATERIAL AND METHOD FOR FORMING THE SAME - In one embodiment of the disclosure, a composite raw material and a method for forming the same are provided. The method includes sulfonating a polycyclic aromatic compound to form a polycyclic aromatic carbon sulfonate (PCAS); and mixing the polycyclic aromatic carbon sulfonate and a polyacrylonitrile (PAN) to form a composite raw material. In another embodiment of the disclosure, a carbon fiber containing the composite raw material described above and a method for forming the same are provided. | 2013-06-27 |
20130164208 | METHODS OF FORMING GRAPHENE - Disclosed is a method of forming graphene. A graphite positive electrode (or positive electrode together with graphite material) wrapped in a semipermeable membrane and a negative electrode are dipped in an acidic electrolyte to conduct an electrolysis process. As such, a first graphene oxide having a size larger than a pore size of the semipermeable membrane is exfoliated from the graphite positive electrode (or the graphite material). The electrolysis process is continuously conducted until a second graphene oxide is exfoliated from the first graphene oxide, wherein the second graphene oxide has a size which is smaller than the pore size of the semipermeable membrane to penetrate through the semipermeable membrane. The second graphene oxide diffused into the acidic electrolyte outside of the semipermeable membrane is collected. Finally, the collected second graphene oxide is chemically reduced to obtain a graphene. | 2013-06-27 |
20130164209 | METHOD FOR PREPARING GRAPHENE RIBBONS WHERE STRUCTURE IS CONTROLLED - Disclosed is a method for fabricating graphene ribbons which are high-functional carbon materials. Provided a method of fabricating graphene ribbons, including (a) preparing a graphene helix carbon structure which is formed by spiral growing of a unit graphene , and (b) applying energy to the carbon structure to obtain ribbon-shaped graphenes. | 2013-06-27 |
20130164210 | GRAPHITE FILM AND PROCESS FOR PRODUCING GRAPHITE FILM - A graphite film which is low in graphite dust generation can be produced by properly selecting acid dianhydride and diamine which constitute a polyimide film, which polyimide film is a raw material of the graphite film. Specifically, the graphite film which is low in graphite dust generation can be obtained if (1) the acid dianhydride is PMDA and the diamine has a molar ratio of ODA/PDA in a range of 100:0 to 80:20, or (2) the acid dianhydride has a molar ratio of PMDA/BPDA in a range of 80:20 to 50:50, and the diamine has a molar ratio of ODA/PDA in a range of 30:70 to 90:10. | 2013-06-27 |
20130164211 | Process for Producing Ammonium Salts - In one embodiment, the invention is to a process for purifying a by-product stream. The process comprises the step of providing a by-product stream comprising an ammonium salt, dimerized amide, and optionally water. The process further comprises the step of precipitating at least a portion of the dimerized amide in the by-product stream to form solid dimerized amide. The process further comprises the step of separating the solid dimerized amide from the by-product stream to form a treated by-product stream comprising less than 1 wt. % solid dimerized amide. | 2013-06-27 |
20130164212 | UZM-39 ALUMINOSILICATE ZEOLITE - A new family of coherently grown composites of TUN and IMF zeotypes have been synthesized. These zeolites are represented by the empirical formula. | 2013-06-27 |
20130164213 | UZM-39 ALUMINOSILICATE ZEOLITE - A new family of coherently grown composites of TUN and IMF zeotypes have been synthesized. These zeolites are represented by the empirical formula. | 2013-06-27 |
20130164214 | Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells - Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8 | 2013-06-27 |
20130164215 | COMPOSITIONS AND METHODS FOR DETECTING, DIAGNOSING, AND TREATING CANCER - The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLL-P1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells. | 2013-06-27 |
20130164216 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF - Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer. | 2013-06-27 |
20130164217 | METHOD OF DIAGNOSING, PREVENTING AND/OR TREATING DEMENTIA & RELATED DISORDERS - Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders. | 2013-06-27 |
20130164218 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES ASANTICANCER AND IMAGING AGENTS - This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein. | 2013-06-27 |
20130164219 | CELL-PENETRATING PEPTIDES AND USES THEREOF - The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles. | 2013-06-27 |
20130164220 | COLLAGEN MIMETIC PEPTIDES FOR TARGETING COLLAGEN STRANDS FOR IN VITRO AND IN VIVO IMAGING AND THERAPEUTIC USE - The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Z | 2013-06-27 |
20130164221 | USE OF BACTERIAL BETA-LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS - Provided herein are methods for detecting, quantifying, differentiating, diagnosing and imaging pathogenic bacteria or condition associated therewith using substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the pathogenic bacteria. Provided is a method for screening therapeutic agents to treat the pathophysiological conditions by measuring a signal emitted from the substrates or products in the presence and absence of the potential therapeutic agent and a diagnostic method for detecting a mycobacterial infection in a subject by contacting biological samples with a substrate and imaging for signals emitted from a mycobacterial beta-lactamase product. Also provided are fluorogenic substrates or substrates comprising a colored dye or a chemical reagent effective to induce a color or pH change. | 2013-06-27 |
20130164222 | Preparation of Extremely Small and Uniform Sized, Iron Oxide-Based Paramagnetic or Pseudo-Paramagnetic Nanoparticles and MRI T1 Contrast Agents Using the Same - Provided are a preparation method of iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles, iron oxide-based nanoparticles prepared by the same, and a T1 contrast agent including the same. More particularly, the disclosure describes a method for preparation of iron oxide nanoparticles having a extremely small and uniform size of 4 nm or less based on thermal decomposition of iron oleate complex, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles prepared by the same, and a T1 contrast agent including iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles. | 2013-06-27 |
20130164223 | IRON OXIDE NANOCAPSULES, METHOD OF MANUFACTURING THE SAME, AND MRI CONTRAST AGENT USING THE SAME - Provided are iron oxide nanocapsules for an MRI contrast agent having high contrast, in which a plurality of iron oxide nanoparticles having a hydrophobic ligand attached thereto are encapsulated in an encapsulation material including a biodegradable polymer and a surfactant, and which satisfy Relations 1, 2, 3, 4 and 5 below. Also a method of manufacturing the iron oxide nanocapsules is provided. | 2013-06-27 |
20130164224 | CONTRAST MEDIUM COMPOSITION WITH CONTRAST ENHANCEMENT EFFECT BY COMPRISING HIGHLY CONCENTRATED CONTRAST AGENT - The present invention relates to a contrast medium composition (formulation) comprising a highly concentrated contrast agent for use in an imaging method. | 2013-06-27 |
20130164225 | FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF - A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2013-06-27 |
20130164226 | FOAMABLE AEROSOL COMPOSITION - There is provided a foamable aerosol composition which is easily emulsified by shaking a container thereof even in the case where poorly water-soluble active ingredients are blended therein at a high concentration, and thus can be sprayed as a uniform composition. The foamable aerosol composition comprises a concentrate and a liquefied gas, wherein, the concentrate comprises active ingredients, surfactants, a monovalent alcohol having 2 to 3 carbon atoms and water, the surfactants comprise polyoxyethylene-added fatty acid ester and a nonionic surfactant having HLB of 8 to 19, the liquefied gas is a poorly water-soluble liquefied gas, a ratio of the concentrate to the liquefied gas is 60/40 to 10/90 (weight ratio), and the concentrate and the liquefied gas are emulsified. | 2013-06-27 |
20130164227 | PRODUCTION METHOD AND EFFERVESCENT FORMULATIONS COMPRISING CEPHALOSPORIN AND CLAVULANIC ACID - The present invention relates to the process for the preparation of the pharmaceutical formulations comprising a cephalosporin antibiotic and clavulanic acid or any pharmaceutically acceptable derivative thereof. The present invention also relates to processes for preparation of said formulations and their use in bacterial infections. | 2013-06-27 |
20130164228 | COMPOSITIONS COMPRISING GALLATES AND GALLAMIDES - Described herein are compositions for topical use comprising an antibacterially effective concentration of a gallate or gallamide compound which is a polysubstituted cycloalkyl or heterocycloalkyl wherein the substituents are selected from hydroxy, hydroxymethyl, fluoro, chloro, amino, nitro, or a moiety of formula -X-(CO)-(3,4,5-trihydroxyphenyl), wherein X is selected from O and NH, provided that the substituents comprise at least two moieties of formula -X-(CO)-(3,4,5-trihydroxyphenyl) attached to adjacent carbons in free or in orally or topically acceptable salt form, as well as methods of making and using the same. | 2013-06-27 |
20130164229 | LIP FORMULATION - Disclosed is an anhydrous lip product and methods of its use that include a gellant comprising | 2013-06-27 |
20130164230 | 2,2'-FUROIN DERIVATIVES AND USE THEREOF TO LIGHT SKIN - The invention relates to the use of compounds of the formula (I), in which R1, R2, m and n have the meanings indicated in the Claims, and/or physiologically acceptable salts, tautomers, stereoisomers and/or solvates thereof, including mixtures thereof in all ratios, for the inhibition of tyrosinase and for lightening the skin. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of pigment disorders of the skin. The invention furthermore relates to preparations comprising the compounds of the formula (I) in combination with at least one further active compound and to a process for the preparation of the preparations by mixing the compounds of the formula (I) with a vehicle which is physiologically acceptable for topical applications. | 2013-06-27 |
20130164231 | Use of specific bis(biphenyl)triazine derivatives and mixtures thereof as UV absorbers - Disclosed is the use of mixtures comprising at least 2 structurally different bis(biphenyl)triazine derivatives of formula (1) wherein X is hydrogen; C | 2013-06-27 |
20130164232 | SUBSTANTIVE SUNSCREEN FORMULATION - Disclosed is a composition comprising 55 to 65% by weight of water, 20 to 25% by weight of a combination of octisalate, avobenzone, homosalate, oxybenzone, and octocrylene, and 3 to 6% by weight of a combination of polyvinylpyrrolidon/eicosene copolymer and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer/squalane/polysorbate 60, wherein the water is included in the continuous phase of the emulsion, and wherein the emulsion has a sun protection factor of at least 30 or from about 30 to 40. | 2013-06-27 |
20130164233 | SKIN-WHITENING ESSENCE COMPOSITION CONTAINING TYROSINASE INHIBITOR - A skin-whitening essence composition containing a tyrosinase inhibitor is disclosed. The skin-whitening essence composition includes: 0.1-2.5 wt % of the tyrosinase inhibitor (CitrusC), 0.1-2.5 wt % of ascorbic acid 2-glucoside (AA2G), 0.1-2.5 wt % of tranexamic acid and a moisturizing essence base that work synergistically to provide the skin-whitening essence composition with skin-whitening effect. | 2013-06-27 |
20130164234 | COMPOSITION FOR TREATING SKIN PIGMENTATION - The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus | 2013-06-27 |
20130164235 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORGANOPOLYSILOXANE ELASTOMER AND AT LEAST ONE TACKIFYING RESIN - The invention relates to a cosmetic composition for caring for and/or making up keratin materials, comprising, in a physiologically acceptable medium: (i) at least one tackifying resin; (ii) at least one organopolysiloxane elastomer; and (iii) at least one liquid fatty phase. | 2013-06-27 |
20130164236 | ANTIPERSPIRANT COMPOSITIONS INCLUDING SILICA SORBED WITH DETERGENT AND METHODS OF MAKING SAME - Antiperspirant compositions, products, and methods for making antiperspirant compositions and products are provided herein. In one embodiment, an antiperspirant composition includes an active antiperspirant compound. The antiperspirant composition also includes silica particles configured to at least partially dissolve in an alkaline environment. Further, an active detergent agent is sorbed by the silica particles and is configured to be released from the silica particles upon partial dissolution of the silica particles. | 2013-06-27 |
20130164237 | USE OF NOVEL AMINO ACID DERIVATIVES AS AGENTS FOR TREATING HUMAN PERSPIRATION, AND COMPOSITIONS CONTAINING THEM - The invention relates to the use, as an agent for treating human perspiration, in a cosmetic composition, of amino acid derivatives of formula (I) below: | 2013-06-27 |
20130164238 | COSMETIC AEROSOL SPRAY - A cosmetic product includes a water-in-oil emulsion containing: a) at least one cosmetic active ingredient, b) at least one water-in-oil emulsifier, c) at least one non-ionic polyalkylene glycol ether having a HLB value >7, d) at least one C | 2013-06-27 |
20130164239 | MALODOR COUNTERACTING COMPOSITIONS AND METHOD FOR THEIR USE - The invention relates to a malodor counteractancy method that resorts to the use of specific malodor counteracting mixtures of fragrance ingredients. More particularly, the invention relates to method of use of new compositions capable of neutralizing or masking in an efficient manner malodors of a large variety of such as body or animal malodors, kitchen malodors, toilet and bathroom malodors, and tobacco malodor. The novel compositions of the invention contain at least one nitrile material in combination with another fragrance material and can be used in any finished consumer products such as air fresheners, kitchen or toilet/bathroom cleaning or freshening products, textile treatment products and products for application on the human skin or hair, or on animal fur, litter containers or cages. | 2013-06-27 |
20130164240 | HAIR CONDITIONING COMPOSITIONS - Compositions for providing hair care benefits, such as smoothing, anti-static control, color protection, frizz control and moisturization are disclosed. The compositions maintain clarity, show no separation upon standing, and remain flowable liquids at room temperature. The compositions comprise a premix consisting essentially of (a) siloxane polymers containing one or more functional groups selected from amino, phenyl, methoxy, hydroxyl, fatty alcohol, fatty acid, alkyl and combinations thereof and (b) materials selected from dimethicones having a viscosity of from about 20 to about 10,000 centipoise, mono-esters containing 20 or fewer carbon atoms, ethers containing 20 or fewer carbon atoms, linear or branched hydrocarbons containing 12 to 20 carbon atoms, and combinations thereof. The compositions can be applied directly to hair (i.e., “neat”) or via conventional hair treatment compositions, such as shampoos or conditioners. | 2013-06-27 |
20130164241 | MASCARA FORMULATION - Mascara primer and mascara formulations are disclosed. | 2013-06-27 |
20130164242 | Polymers And Compositions - The present invention relates to hair care and personal care compositions which contain an acrylic copolymer which is polymerized in the presence of at least two different classes of crosslinking monomers. The polymer functions both as a fixative/film former and a thickening agent for hair styling and personal care compositions in which it is contained. The copolymer exhibits advantageous fixative, film forming and rheological gel properties. | 2013-06-27 |
20130164243 | CONDITIONING COMPOSITION FOR HAIR - Present invention is related to a conditioning composition for hair comprising at least one cationic and/or cationizable surfactant of amido amine type, at least one aminated silicone and at least one fatty acid lower alcohol ester. | 2013-06-27 |
20130164244 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to aqueous conditioning composition for hair comprising at least one cationic starch polymer and at least one additional cationic polymer selected from the ones with monosaccharide units. Conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. | 2013-06-27 |
20130164245 | Compositions and Methods for the Protection of Hair From Treated Pool Water - Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed. | 2013-06-27 |
20130164246 | Hair Styling Cosmetic Composition - To provide a hair styling cosmetic composition which is excellent in hair styling property and hair restyling property, even though having a low viscosity, and is excellent in non-stickiness, smoothness, and light finish of the hair. A hair styling cosmetic composition comprising (a) one or more substances being solid at room temperature (25° C.) selected from among (a | 2013-06-27 |
20130164247 | TRANSPARENT MICROEMULSIONS WITH A FILM-FORMING STYLING POLYMER AND METHODS FOR MAKING THE SAME - Transparent microemulsions and methods for making the same are provided. In accordance with an exemplary embodiment, a transparent microemulsion comprises an aqueous phase, an oil phase, an emulsifier, and vinyl caprolactom/vinyl pyrrolidone/dimethyl-aminoethyl methacrylate copolymer. An exemplary method for forming a transparent microemulsion hair styling product comprises forming an oil phase comprising a lipophilic ingredient, forming an aqueous phase, providing an emulsifier, and combining the oil phase, the aqueous phase, and the emulsifier to form a mixture. The mixture is combined with vinyl caprolactom/vinyl pyrrolidone/dimethylaminoethyl methacrylate copolymer. | 2013-06-27 |
20130164248 | COSMETIC COMPOSITION COMPRISING A PARTICULAR SILICON DERIVATIVE AND ONE OR MORE ACRYLIC THICKENING POLYMERS - The invention relates to a cosmetic composition comprising: (i) one or more products (A) of the reaction of: (a) one or more oxirane or oxetane compounds comprising at least two oxirane or oxetane groups; and (b) one or more aminosilanes corresponding to the formula (1a): N(H)(R | 2013-06-27 |
20130164249 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY - Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers. | 2013-06-27 |
20130164250 | METHOD FOR PRODUCTION OF BIORESORBABLE MICROPARTICLES, MICROPARTICLES THUS OBTAINED AND USE THEREOF - Nonlamellar bioresorbable microparticles to which protein substances are bonded, and a method for preparing the microparticles, comprising: (i) preparing the microparticles from at least one bioresorbable polymer without stabilizer and without surfactant; and (ii) bonding the protein substances to the microparticles obtained in step (i) without surfactant. | 2013-06-27 |
20130164251 | MUTANT G-CSF FUSION PROTEIN, AND PREPARATION AND USE THEREOF - The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia. | 2013-06-27 |
20130164252 | Method for Hair Growth using Granulocyte-Colony Stimulating Factor - The present invention provides a method for re-growing hair in patients with androgenic alopecia by administering effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. After the state of re-growth is obtained, the hair growth is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. The invention further provides a method for increasing cuticle growth and density using a similar administration of effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. The increased cuticle growth and density is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. | 2013-06-27 |
20130164253 | Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF - The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition. | 2013-06-27 |
20130164254 | ANTICANCER FUSION PROTEIN - The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases. | 2013-06-27 |
20130164255 | IMMUNOTHERAPY FOR REVERSING IMMUNE SUPPRESSION - A method for overcoming immune suppression includes the steps of inducing production of naive T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T cells and exposing the naive T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α | 2013-06-27 |
20130164256 | IMMUNOBINDERS DIRECTED AGAINST TNF - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 2013-06-27 |
20130164257 | MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS - A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described. | 2013-06-27 |
20130164258 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C - The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient. | 2013-06-27 |
20130164259 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to 1,4-Substituted Piperazine Derivatives, compositions comprising one or more 1,4-Substituted Piperazine Derivatives, and methods of using the 1,4-Substituted Piperazine Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 2013-06-27 |
20130164260 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2013-06-27 |
20130164261 | SUBSTITUTED NUCLEOTIDE ANALOGS - Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs. | 2013-06-27 |
20130164262 | Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same - Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. | 2013-06-27 |
20130164263 | Fungus Having Fusarium graminearum Virus FgV1-DK21 Transmitted Thereto for Biological Control and Method for Biological Control Using the Same - A fungus, for biological control, having | 2013-06-27 |
20130164264 | DEFECTIVE INTERFERING VIRUS - Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Co-administration of cloned DI influenza A virus with a lethal dose of virulent influenza A virus conferred protection in mice compared to a control of inactivated cloned DI influenza A virus. Control mice which received only cloned DI influenza A virus and no lethal challenge of virulent influenza A virus were not protected three weeks later on lethal challenge with infective virus. Cloned DI influenza A virus of one subtype is found to act in vivo as an effective antiviral against the same or any other sub-type of influenza A virus. The antiviral effect has been found to have both a therapeutic and a prophylactic application against influenza A infection in humans, mammals and birds. | 2013-06-27 |
20130164265 | SKIN CARE COMPOSITIONS - This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds. | 2013-06-27 |
20130164266 | 3-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES - The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types. | 2013-06-27 |
20130164267 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals. | 2013-06-27 |
20130164268 | REGULATION OF GLYPICAN 4 ACTIVITY TO MODULATE THE FATE OF STEM CELLS AND USES THEREOF - The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy. | 2013-06-27 |
20130164269 | CELL CULTURE SYSTEM FOR BIOREACTOR SCALE-UP OF CELLS - The present invention relates to growing stem cells, for e.g., MSCs, in large-scale under GMP-compliance, using media and reagents that satisfy GMP requirements, while maintaining stemness, for effective downstream therapeutic use, which include but are not limited to, stem cell therapy, production of products, such as beneficial factors, recombinant proteins, etc. obtained from such stem cells. | 2013-06-27 |
20130164270 | POLYNUCLEOTIDES AND CONSTRUCTS ENCODING SFLT1-14 AND METHOD FOR EFFICIENT PROPAGATION AND EXPRESSION THEREOF - The present invention relates to engineered polynucleotides and constructs comprising nucleic acid sequences encoding a specific splice-variant (sFLT1-14) of the VEGFR family Flt-1, methods for efficient propagation and expression thereof and compositions and uses thereof. More particularly, the invention relates to isolated polynucleotides comprising a nucleic acid sequence coding for sFlt1-14 or any fragment thereof comprising the serine-rich C-terminus region of said sFlt1-14, wherein at least one of the TCA serine coding codons in said serine-rich C-terminus region of sFlt1-14 as encoded by the nucleic acid sequence of SEQ ID NO. 1, is replaced by any one of TCT, TCC, TCG, AGT, AGC. The invention further provides compositions and method of treating VEGF-associated medical conditions using the polynucleotides of the invention. | 2013-06-27 |
20130164271 | TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS - The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them. | 2013-06-27 |
20130164272 | METHODS OF IDENTIFYING CENTRAL MEMORY T CELLS AND OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells comprising: (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs of each sub-population with an antigen; (iii) obtaining a sample of the contacted PBMCs from each sub-population; (iv) measuring the quantity of 1) IL-2 mRNA and 2) IFN-γ mRNA expressed by the PBMCs of each sample; (v) determining the IL-2 index of each sample; (vi) identifying one or more samples with an IL-2 index determined in (v) of greater than or equal to about 10 to identify one or more antigen-reactive, central memory T cell sub-populations; (vii) dividing the antigen-reactive, central memory T cell sub-population(s) identified in (vi) into microcultures; (viii) identifying one or more antigen-reactive microcultures; and (ix) expanding the microculture(s). | 2013-06-27 |
20130164273 | REVERSIBLY INACTIVATED ACIDIFIED PLASMIN COMPOSITION - The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. | 2013-06-27 |
20130164274 | KIT FOR MONITORING, DETECTING AND STAGING GVHD - A method and kit for detecting Graft versus Host Disease (GVHD) in a mammal including a human comprising the steps of; obtaining a sample from the patient or subject; measuring the level of GSK-3.beta. inactivation by measuring beta-catenin levels in the absence of serine 9 phosphorylation, or by measuring the site of stimulation on the GSK-3beta once stimulated through the activated Wnt pathway, or by measuring a protein marker that is unique to the inactivation of GSK-3 beta through the activated Wnt pathway, comparing the result of said inactivation levels with a predetermined normal inactivation value obtained from healthy subjects, such that a deviation of at least about 25% from normal inactivation values indicates the presence of GVHD. | 2013-06-27 |
20130164275 | METHOD FOR TREATING ACIDOSIS IN RUMINANTS - The present invention provides a method for treating acidosis in a ruminant. The method includes administering an effective amount of a naturally derived inhibitor of a carbohydrate degrading enzyme to the ruminant. Such enzymes include amylase and glucosidase. In addition, the carbohydrate degrading enzyme may be endogenous or exogenous to the ruminant. | 2013-06-27 |
20130164276 | AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 2013-06-27 |